Tibet Rhodiola Pharmaceutical Holding Co. (600211.SH) Latest Company News

Oct 30, 2026, 07:59 UTC
Tibet Rhodiola Pharmaceutical reported first-nine-month 2026 revenue of 2.176 billion yuan, up 4.15% year over year, and net profit attributable to shareholders of 776 million yuan, up 7.48%.
Source:
- finance.sina.cn
Oct 30, 2026, 07:59 UTC
Tibet Rhodiola Pharmaceutical reported third-quarter 2026 revenue of 622 million yuan, up 41.73% year over year, and net profit attributable to shareholders of 168 million yuan, up 8.64%.
Source:
- finance.sina.cn
Sep 6, 2026, 07:32 UTC
Tibet Rhodiola Pharmaceutical announced a differentiated interim dividend for H1 2026, paying 1.146 yuan per share (tax included) based on 322 million total shares minus 4.0001 million shares in the buyback account, totaling 365 million yuan, representing 60% of half-year net profit attributable to shareholders.
Source:
- finance.sina.cn
Sep 1, 2026, 09:12 UTC
Tibet Pharmaceutical announced that as of the end of August 2026, it had repurchased 4,000,058 shares of its own stock, representing 1.24% of total shares, for a total amount of 177,595,651.46 yuan.
Source:
- finance.sina.cn
Aug 13, 2026, 08:35 UTC
Tibet Rhodiola Pharmaceutical proposed a cash dividend of 1.15 yuan per share (pre-tax) to all shareholders, based on total share capital excluding treasury shares.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 13, 2026, 08:35 UTC
Tibet Rhodiola Pharmaceutical announced its 2026 half-year results: revenue of 1.554 billion yuan, down 5.83% year-on-year; net profit attributable to shareholders of 608 million yuan, up 7.16% year-on-year; non-recurring net profit of 440 million yuan, down 19.00% year-on-year.
Source:
- finance.sina.cn
- wap.eastmoney.com
Jul 7, 2026, 11:52 UTC
Zhejiang Guyuelongshan Shaoxing Wine Co., Ltd. and Tibet Nuodikang Pharmaceutical Co., Ltd. signed a strategic cooperation agreement to jointly develop a health-oriented special yellow wine.
Source:
- finance.sina.cn

600211.SH

Tibet Rhodiola Pharmaceutical reported first-nine-month 2026 revenue of 2.176 billion yuan, up 4.15% year over year, and net profit attributable to shareholders of 776 million yuan, up 7.48%.

Tibet Rhodiola Pharmaceutical reported third-quarter 2026 revenue of 622 million yuan, up 41.73% year over year, and net profit attributable to shareholders of 168 million yuan, up 8.64%.

Tibet Pharmaceutical announced that as of the end of August 2026, it had repurchased 4,000,058 shares of its own stock, representing 1.24% of total shares, for a total amount of 177,595,651.46 yuan.

Tibet Rhodiola Pharmaceutical proposed a cash dividend of 1.15 yuan per share (pre-tax) to all shareholders, based on total share capital excluding treasury shares.

Tibet Rhodiola Pharmaceutical announced its 2026 half-year results: revenue of 1.554 billion yuan, down 5.83% year-on-year; net profit attributable to shareholders of 608 million yuan, up 7.16% year-on-year; non-recurring net profit of 440 million yuan, down 19.00% year-on-year.

Zhejiang Guyuelongshan Shaoxing Wine Co., Ltd. and Tibet Nuodikang Pharmaceutical Co., Ltd. signed a strategic cooperation agreement to jointly develop a health-oriented special yellow wine.